Brain and nerves

268 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Brain and nerves
Treatment and conditionWhere it standsTrials
1 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
120 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
30mg PRAX-628 for epilepsy, generalizedPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
30mg PRAX-628 for seizuresPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
60 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Aav-gad for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AAV9-Follistatin gene therapy for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AAV9-Follistatin gene therapy + VEGF Plasmid for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-1005 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ACP-204 for hallucinationsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Activa PC+S Neurostimulator for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Active tDCS with Sternberg task for neuralgiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Active, self-directed electrical stimulation of the median nerve for ticsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Acupuncture for agnosiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS (aDBS) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS delivered through AlphaDBS IPG System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
adaptive deep brain stimulation + conventional deep brain stimulation for dyskinesiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive deep brain stimulation + conventional deep brain stimulation for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
aDBS-Extended (Medtronic Percept™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Agilik for cerebral palsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Agilik for spinal dysraphismTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Agilik + standard care for cerebral palsyTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Allay Lamp for migraine disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ambroxol for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Apitegromab for muscular atrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Apitegromab for spinal muscular atrophies of childhoodPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
apomorphine infusion for dyskinesiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
apomorphine infusion for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ARC-BSI Lumbar system for paraplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aticaprant for anhedoniaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
ATLAS 2030 exoskeleton for cerebral palsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
autologous dopaminergic cell implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous midbrain dopamine neurons for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Baclofen for psychomotor agitationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bexicaserin for epilepsies, myoclonicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bexicaserin for seizuresPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 225 mg for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood sampling for microRNA testing for migraine disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Bocunebart for migraine disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BR005-036C for migraine disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BrainGate Neural Interface System for aphasiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BrainGate Neural Interface System for aphasia, brocaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BrainGate Neural Interface System for dysarthriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BrainGate Neural Interface System for locked-in syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brivaracetam for epilepsy, absencePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Buprenorphine hydrochloride for agnosiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cannabidiol for drug resistant epilepsyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cannabidiol for epilepsies, myoclonicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Cannabidiol for epilepsyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Cannabidiol for epilepsy, absenceTrials ended early, as of 19 Nov 2026 (not yet checked by a person)2
Cannabidiol for lennox gastaut syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Cannabidiol for seizuresPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Cannabidiol for spasms, infantilePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cenobamate (syrup) for 2 to < 18 year olds + Cenobamate (tablet) for 12 to < 18 year olds for epilepsies, partialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chronic speech BCI for locked-in syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chronic speech BCI for speech disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CMP-002 for nervous system diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for corticobasal degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for dystoniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for multiple system atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CVN424 150 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
CVN424 75 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Depression Cognitive Training + tDCS (active stimulation) for neurobehavioral manifestationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Depression Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Device: Directional Deep Brain Stimulation for epilepsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexmedetomidine hydrochloride for dysautonomia, familialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diet + Exercise + Meditation for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divalproex sodium for maniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab for down syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DSP-1083 implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elismetrep for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
endoscopic repair of myelomeningocele before 26 SA for meningomyeloceleTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Epidural Electrical Stimulation (EES) using an implanted paddle lead and pulse generator combined with a 12-month intensive rehabilitation program. for paraplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Epidural spinal cord stimulation for paraplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Epidural spinal cord stimulation for primary dysautonomiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Epidural Spinal Cord Stimulation System for primary dysautonomiasPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Epidural Spinal Stimulation (ESS) + Upper extremity rehabilitation for quadriplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Eptinezumab for migraine disordersTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Erenumab for epilepsyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erenumab for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)22
Erenumab + calcitonin gene-related peptide for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erenumab 70 mg + GALCANEZUMAB + ATOGEPANT + EPTINEZUMAB for migraine disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Erenumab matching placebo + ERENUMAB for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erenumab-Aooe 140 MG/ML [Aimovig] for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Escitalopram oxalate for aphasiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Escitalopram oxalate for lethargyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Essential Amino Acid Supplementation for muscular atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX101 for epilepsies, myoclonicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Ex-cipn for peripheral nervous system diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Exogenous ketone ester for drug resistant epilepsyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exogenous ketone ester for status epilepticusPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fetoscopic repair of spina bifida for arnold-chiari malformationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fetoscopic repair of spina bifida for hydrocephalusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fetoscopic repair of spina bifida for meningomyeloceleTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fetoscopic repair of spina bifida for spina bifida cysticaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fetoscopy for arnold-chiari malformationTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Fetoscopy for meningomyelocelePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)4
Fetoscopy for spina bifida cysticaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fetoscopy for spinal dysraphismPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)4
FLORTAUCIPIR F-18 for neurodegenerative diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLUOROETHOXYBENZOVESAMICOL F-18 for down syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluoxetine for down syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Focused Transcranial Ultrasound for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Galcanezumab for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Galcanezumab + erenumab + fremanezumab for migraine disordersTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
GALCANEZUMAB + Ubrogepant for migraine disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GC101 for muscular atrophy, spinalPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Glyceryl Trinitrate Only Product in Oromucosal Dose Form for autonomic dysreflexiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Green light for migraine disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High-Intensity Aerobic Exercise (AE) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Iluzanebart for leukoencephalopathiesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
IM ketamine in dose finding and then continuation for phantom limbPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Imifoplatin for peripheral nervous system diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
intermittent theta burst stimulation (iTBS) for lethargyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for lethargyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Internet-Based Intervention + Quality-of-Life Assessment + Questionnaire Administration for trismusPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ION337 for epilepsies, myoclonicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerationsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivermectin for olfaction disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JZP926 capsule for myoclonic epilepsy, juvenilePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketamine for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketoprofen for agnosiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for down syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for down syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Leia Sensory Prosthesis for peripheral nervous system diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
lentiviral gene therapy for drug resistant epilepsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Leucovorin for language disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Levetiracetam for seizuresPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Levoleucovorin calcium for language disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Lidocaine for migraine disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for dystoniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for epilepsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for essential tremorTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lithium for maniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lithium sulphate prolonged-release 660 mg for tremorTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Lixisenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3884961 + Sirolimus + Methylprednisolone for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) for lethargyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Methylcobalamin for peripheral nervous system diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
MF-300 for sarcopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Minimally invasive fetoscopic repair of MMC for meningomyeloceleTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Minimally invasive fetoscopic repair of MMC for spinal dysraphismTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MiraBurst for dysgeusiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ML-007C-MA for brain diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Modified deep cervical Lymphatic-Venous Anastomosis for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MRI + Psilocybin + Risperidone for anhedoniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
N1 Implant + R1 Robot for dysarthriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
N1 Implant + R1 Robot for quadriplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Neridronic acid for reflex sympathetic dystrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neural Prosthetic System 2 (NPS2) for quadriplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nicotinamide riboside for peripheral nervous system diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NightWare for primary dysautonomiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Non-Specific Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NTLA-2001 for polyneuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OAV101 for bulbo-spinal atrophy, x-linkedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
OAV101 for muscular atrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Onabotulinumtoxin-A for migraine disordersTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linkedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for muscular atrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for muscular atrophy, spinalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Onasemnogene abeparvovec for spinal muscular atrophies of childhoodPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Opakalim for drug resistant epilepsyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Opakalim for epilepsies, partialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Opakalim for seizuresPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Oxytocin for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paired Vagus Nerve Stimulation for paresisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Paxalisib for focal cortical dysplasiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PBT-434 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + Porustobart for spinocerebellar degenerationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Percutaneous epidural electrical spinal stimulation for paraplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Percutaneous epidural electrical spinal stimulation for quadriplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 high dose (15 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 low dose (1 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 1 (3 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 2 (7 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for migraine disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Placebo for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Psilocybin for migraine disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo Nasal Spray for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prasinezumab for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
PRT-064040 nasal spray for migraine disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psilocybin for agnosiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psilocybin for anhedoniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin for migraine disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin for neuralgiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin for paraplegiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psilocybin for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin for quadriplegiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psilocybin + PIMAVANSERIN for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RAP-219 for epilepsies, partialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RAP-219 for seizuresPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rapid sedation for status epilepticusPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
RECLAIM System for locked-in syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Relutrigine for spasms, infantilePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Risdiplam for muscular atrophy, spinalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
ROC-101 for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rocuronium 1.5mg/kg/hr for muscle hypotoniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rugonersen for angelman syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Satralizumab for myelin oligodendrocyte glycoprotein antibody-associated diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Silkworm pupa tablets for sarcopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SKG0201 Injection for spinal muscular atrophies of childhoodPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SonoCloud-4 (SC4) device for neuroinflammatory diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) for spinal muscular atrophies of childhoodTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for memory disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Stent Implantation for pseudotumor cerebriPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Step count goal for chronobiology disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
stimulation device for akinetic mutismTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
stimulation device for persistent vegetative stateTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
STK-001 - Single Ascending Doses for epilepsies, myoclonicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SUN-627 for neuroinflammatory diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Suzetrigine for agnosiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Synsepalum dulcificum fruit for dysgeusiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Targeted Epidural Spinal Stimulation for autonomic dysreflexiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tavapadon for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Tersolisib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TEV-56286 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
The LFP Beta aDBS System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
the Terumo Hydropearl® microspheres device for agnosiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tominersen for choreaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Total knee replacement for muscular atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcranial Direct Current Stimulation for migraine disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcranial focused ultrasound stimulation for essential tremorTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcutaneous electrical spinal stimulation for paraplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcutaneous electrical spinal stimulation for quadriplegiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ubrogepant + ERENUMAB for migraine disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Unicompartmental knee replacement for muscular atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vagus nerve stimulation; for persistent vegetative stateTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Valproic acid for maniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vasopressin for agnosiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VCA-894A for charcot-marie-tooth diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VER-01 for neuralgiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VX-670 for myotoniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
YA-101 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zorevunersen for epilepsies, myoclonicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3